Avalo Therapeutics (AVTX) Shares Outstanding (Weighted Average) (2014 - 2026)

Avalo Therapeutics has reported Shares Outstanding (Weighted Average) for 13 years, with the latest figure at $20.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 91.22% year-over-year to $20.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.1 million (up 91.22% YoY), and the FY2025 full-year result was $13.4 million, up 202.86% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $20.1 million, up from $13.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $20.1 million in Q1 2026, with the low at $39202.0 in Q4 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $6.1 million across 5 years, with a median of $4.4 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) sank 99.48% — and 2024, when it surged 1659.4%.
• Avalo Therapeutics' Shares Outstanding (Weighted Average) stood at $39202.0 in 2022, then soared by 608.45% to $277727.0 in 2023, then jumped by 1493.7% to $4.4 million in 2024, then surged by 202.86% to $13.4 million in 2025, then soared by 50.0% to $20.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $20.1 million (Q1 2026), $13.4 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.